The FDA last week approved Sanofi’s Sarclisa (in tandem with Amgen’s Kyprolis and dexamethasone) for the treatment of relapsed or refractory multiple myeloma in patients who have had at least one prior treatment. This will put Sarclisa in direct competition with Johnson & Johnson’s Darzalex, which scored the same indication in August 2020. For the treatment of multiple myeloma, Darzalex currently holds preferred formulary placement for 7% of covered lives, growing to 17% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 4/5/21